Co-Authors
This is a "connection" page, showing publications co-authored by Christopher Green and Andrew Pollard.
Connection Strength
1.446
-
Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults. J Infect. 2019 05; 78(5):382-392.
Score: 0.808
-
Author Correction: Airway response to respiratory syncytial virus has incidental antibacterial effects. Nat Commun. 2019 Jul 18; 10(1):3291.
Score: 0.208
-
Airway response to respiratory syncytial virus has incidental antibacterial effects. Nat Commun. 2019 05 17; 10(1):2218.
Score: 0.206
-
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021 04 10; 397(10282):1351-1362.
Score: 0.059
-
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021 03 06; 397(10277):881-891.
Score: 0.058
-
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 01 09; 397(10269):99-111.
Score: 0.057
-
Antibodies in lymphocyte supernatants can distinguish between neutralising antibodies induced by RSV vaccination and pre-existing antibodies induced by natural infection. Vaccine. 2018 11 12; 36(46):6988-6994.
Score: 0.049